These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 3474778)

  • 1. Auranofin therapy in juvenile rheumatoid arthritis: a 48-week phase II study.
    Kvien TK; Høyeraal HM; Sandstad B; Kass E
    Scand J Rheumatol Suppl; 1986; 63():79-83. PubMed ID: 3474778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Auranofin therapy for juvenile rheumatoid arthritis: results of the five-year open label extension trial.
    Giannini EH; Barron KS; Spencer CH; Person DA; Baum J; Bernstein BH; Kredich DW; Jacobs JC; Zemel LS; Gibbas D
    J Rheumatol; 1991 Aug; 18(8):1240-2. PubMed ID: 1941832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of auranofin as demonstrated by improvement in clinical parameters and decrease in anti-inflammatory usage: a long-term, multicenter study.
    Brenol JC; Chahade W; De Freitas GG; De Pádua PM; Rachid A; Samara A; Seda H; Ximenes AC
    Scand J Rheumatol Suppl; 1986; 63():37-45. PubMed ID: 3299682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An open study on the efficacy and safety of auranofin in treating psoriatic arthritis.
    Dequeker J; Gevers G
    Scand J Rheumatol Suppl; 1986; 63():85-95. PubMed ID: 3474779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term open-label preliminary study of the safety and efficacy of leflunomide in patients with polyarticular-course juvenile rheumatoid arthritis.
    Silverman E; Spiegel L; Hawkins D; Petty R; Goldsmith D; Schanberg L; Duffy C; Howard P; Strand V
    Arthritis Rheum; 2005 Feb; 52(2):554-62. PubMed ID: 15693001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Postmarketing experience with auranofin in the Federal Republic of Germany.
    Schattenkirchner M; Missler B; Mulz D
    Scand J Rheumatol Suppl; 1986; 63():57-66. PubMed ID: 3299683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longterm auranofin therapy in patients with juvenile rheumatoid arthritis.
    Giannini EH; Brewer EJ; Person DA; He XH
    J Rheumatol; 1986 Aug; 13(4):768-70. PubMed ID: 3534260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The evaluation of the therapeutic efficacy of auranofin in juvenile rheumatoid arthritis (the results of Soviet-American research)].
    Kuz'mina NN; Brue E; Shaĭkov AV; Isaeva LA; Shakhbazian IE; Giannini E; Iakovleva AA; Puodzhiunene EP; Vorontsov IM; Astrauskene DS
    Ter Arkh; 1990; 62(5):38-41. PubMed ID: 2204140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose response studies and longterm evaluation of auranofin in rheumatoid arthritis.
    Champion GD; Cairns DR; Bieri D; Adena MA; Browne CD; Cohen ML; Day RO; Edmonds JP; Graham GG; de Jager J
    J Rheumatol; 1988 Jan; 15(1):28-34. PubMed ID: 3280795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes of immunological parameters during auranofin treatment in children affected with juvenile chronic arthritis.
    Fantini F; Cottafava F; Martini A; Murelli M; Franchini E; D'Errico R; Panzarasa R
    Int J Clin Pharmacol Res; 1986; 6(1):61-7. PubMed ID: 3082775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Auranofin: first choice for remission-inducing drug (RID) therapy in rheumatoid arthritis?
    Bandilla K; Missler B; Klein-Reesink B
    Scand J Rheumatol Suppl; 1986; 63():47-54. PubMed ID: 3474777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Slow acting antirheumatic drugs in patients with juvenile rheumatoid arthritis--evaluated in a randomized, parallel 50-week clinical trial.
    Kvien TK; Høyeraal HM; Sandstad B
    J Rheumatol; 1985 Jun; 12(3):533-9. PubMed ID: 3930720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical assessment of a group of children with juvenile rheumatoid arthritis receiving long-term treatment with oral gold salt].
    Mignone F; Sardella ML; Clara L; Barrett S; Basano R; Barbero I
    Minerva Pediatr; 1992 Dec; 44(12):617-22. PubMed ID: 1363792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term efficacy and safety of auranofin: a review of clinical experience.
    Blodgett RC; Pietrusko RG
    Scand J Rheumatol Suppl; 1986; 63():67-78. PubMed ID: 3110943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blood and serum concentrations of gold after a single dose of auranofin in children with juvenile rheumatoid arthritis.
    Giannini EH; Person DA; Brewer EJ; Parks DB
    J Rheumatol; 1983 Jun; 10(3):496-8. PubMed ID: 6411921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Methotrexate treatment in refractory juvenile rheumatoid arthritis].
    Brik R
    Harefuah; 1998 Dec; 135(11):509-11, 567. PubMed ID: 10911466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis.
    Woo P; Southwood TR; Prieur AM; Doré CJ; Grainger J; David J; Ryder C; Hasson N; Hall A; Lemelle I
    Arthritis Rheum; 2000 Aug; 43(8):1849-57. PubMed ID: 10943876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sulfasalazine in the treatment of juvenile chronic arthritis: a randomized, double-blind, placebo-controlled, multicenter study. Dutch Juvenile Chronic Arthritis Study Group.
    van Rossum MA; Fiselier TJ; Franssen MJ; Zwinderman AH; ten Cate R; van Suijlekom-Smit LW; van Luijk WH; van Soesbergen RM; Wulffraat NM; Oostveen JC; Kuis W; Dijkstra PF; van Ede CF; Dijkmans BA
    Arthritis Rheum; 1998 May; 41(5):808-16. PubMed ID: 9588731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anakinra for systemic juvenile arthritis: the Rocky Mountain experience.
    Zeft A; Hollister R; LaFleur B; Sampath P; Soep J; McNally B; Kunkel G; Schlesinger M; Bohnsack J
    J Clin Rheumatol; 2009 Jun; 15(4):161-4. PubMed ID: 19363453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NTP Toxicology and Carcinogenesis Studies of 4,4'-Thiobis(6- t -butyl- m -cresol) (CAS No. 96-69-5) in F344/N Rats and B6C3F1 Mice (Feed Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1994 Dec; 435():1-288. PubMed ID: 12595928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.